Protocol Ledger

NCT05851014 · Phase III · RECRUITING

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Interventional Phase III clinical trial protocol NCT05851014 sponsored by Genor Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-14 Enrollment: 350 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05851014
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05851014
Protocol FieldVerified Registry Value
NCT IdentifierNCT05851014
Consolidated Lead SponsorGenor Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment350 participants (ESTIMATED)
Registered Start Date2022-01-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI